Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Protagonist Therapeutics : SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $35 from $50, Keeps Outperform Rating

09/20/2021 | 10:48am EST


ę MT Newswires 2021
All news about PROTAGONIST THERAPEUTICS, INC.
12/03Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summi..
PR
12/02Protagonist Therapeutics Picks PN-235 for Mid-Stage Trials in Multiple Indications
MT
12/02Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Cl..
PR
12/02Protagonist Therapeutics Announces Selection of Oral Peptide PN-235 into Phase 2 Clinic..
CI
11/16Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use ..
AQ
11/15Protagonist Therapeutics Announces 'Positive Data' for Rusfertide as Possible Hereditar..
MT
11/15JMP Securities Adjusts Price Target on Protagonist Therapeutics to $70 From $60, Keeps ..
MT
11/15Protagonist Therapeutics, Inc. Announces Positive Phase 2A Data Supporting the Potentia..
CI
11/11Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
PR
11/05Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Pol..
AQ
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 23,8 M - -
Net income 2021 -127 M - -
Net cash 2021 248 M - -
P/E ratio 2021 -11,9x
Yield 2021 -
Capitalization 1 540 M 1 540 M -
EV / Sales 2021 54,2x
EV / Sales 2022 50,9x
Nbr of Employees 116
Free-Float 98,8%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 32,27 $
Average target price 59,00 $
Spread / Average Target 82,8%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Donald A. Kalkofen Chief Financial Officer
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.60.07%1 540
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298